PLA2G12B: A Potential Drug Target Or Biomarker (G84647)

Target Name: PLA2G12B

NCBI ID: G84647

PLA2G12B

PLA2G12B: A Potential Drug Target Or Biomarker

PLA2G12B, also known as GXIII sPLA2-like, is a protein that is expressed in various tissues throughout the body. It is a member of the PLA2 family, which is known for its role in regulating cellular signaling pathways. In recent years, researchers have been interested in studying PLA2G12B as a potential drug target or biomarker for various diseases, including cancer, cardiovascular disease, and neurological disorders.

PLA2G12B is a 21-kDa protein that is expressed in the cytoplasm of various cell types. It is characterized by a catalytic core that contains a single transmembrane domain and a cytoplasmic tail that is involved in its stability and localization to the endoplasmic reticulum (ER) and other intracellular structures. The catalytic core of PLA2G12B consists of a parallel beta-sheet structure that is composed of multiple conserved beta-helices. This structure is similar to that of other members of the PLA2 family, such as PLA2-1 and PLA2-2, which are known to function as inhibitors of platelet aggregation.

One of the unique features of PLA2G12B is its ability to interact with various signaling pathways. For example, PLA2G12B has been shown to interact with the T-cell receptor (TCR), which is involved in cell signaling and immune responses. Additionally, PLA2G12B has been shown to interact with the integrin alpha-2 (CD41), which is involved in cell adhesion and migration. These interactions suggest that PLA2G12B may play a role in regulating cellular signaling pathways and in the development of various diseases.

PLA2G12B has also been shown to be involved in the regulation of platelet function. Platelets are important for maintaining blood clotting and are involved in many physiological processes, including wound healing and tissue repair. Researchers have shown that PLA2G12B plays a role in regulating platelet aggregation and in the regulation of platelet function.

In addition to its role in cell signaling, PLA2G12B has also been shown to be involved in the regulation of inflammation. Inflammation is a critical response of the immune system to injury or infection, and it can lead to a range of diseases, including cancer, cardiovascular disease, and neurological disorders. Researchers have shown that PLA2G12B is involved in the regulation of inflammation by regulating the activity of immune cells and by regulating the production of pro-inflammatory cytokines.

PLA2G12B has also been shown to be involved in the regulation of cellular apoptosis (programmed cell death). Apoptosis is a natural response of cells to environmental stressors, including exposure to chemotherapy drugs, radiation, or infection. Pro-inflammatory cytokines, such as TNF-alpha, have been shown to play a role in the regulation of apoptosis, and PLA2G12B may be involved in this regulation.

In conclusion, PLA2G12B is a protein that is involved in a wide range of cellular signaling pathways and in the regulation of cellular processes that are important for the maintenance of health and disease. As a potential drug target or biomarker, PLA2G12B is being studied for its potential utility in the treatment of various diseases, including cancer, cardiovascular disease, and neurological disorders. Further research is needed to fully understand the role of PLA2G12B in cellular signaling and to determine its potential as a drug target or biomarker.

Protein Name: Phospholipase A2 Group XIIB

Functions: Not known; does not seem to have catalytic activity

The "PLA2G12B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PLA2G12B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets